Gwendolyn Wu
Senior Reporter | LinkedInGwendolyn Wu is a senior reporter at BioPharma Dive covering biotech startups, venture capital, IPOs and the ecosystem that supports them. She was selected as the 2024 McAllister Editorial Fellow by SIIA in recognition for her work on a series of stories examining the world’s first CRISPR medicine. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
427 articles by Gwendolyn Wu
-
At BIO, tension over China biotech deal regulation looms
June 26, 2026 -
Antares gets $105M from Novartis for new cancer drugs
June 25, 2026 -
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
June 23, 2026 -
Bionyra brings in $165M for next-generation immune drugs
June 22, 2026 -
Kardigan extends biotech’s streak of big IPOs with $400M haul
June 17, 2026 -
Lilly buys non-opioid pain drugmaker 4E
June 16, 2026 -
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
June 11, 2026 -
Parabilis sets a record with a $670M biotech IPO
June 10, 2026 -
Stealthy startup Treeline plans a reverse merger
June 9, 2026 -
City banks nearly $100M for next-gen RNAi drugs
June 8, 2026 -
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
June 8, 2026 -
A Spanish biotech banks $87M to make differentiated ADCs
June 4, 2026 -
Lilly, Ascidian link up in RNA exon editing pact
June 3, 2026 -
RallyBio tries again for reverse merger, this time with Avenzo
June 1, 2026 -
Verge, following trial failure, rebrands its AI drug discovery ambitions
May 27, 2026 -
SR One’s Simeon George on how China is rewriting biotech’s venture playbook
May 26, 2026 -
RA Capital banks $75M for a biotech SPAC
May 21, 2026 -
Oorja, run by Acceleron veterans, launches to make new fibrosis drugs
May 20, 2026 -
Odyssey, on second try, snags $279M in an IPO
May 7, 2026 -
Angelini to buy Catalyst in $4B play for rare neuro drugs
May 7, 2026 -
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
May 6, 2026 -
Cytospire hauls in $83M for a new type of T cell engager
May 5, 2026 -
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
May 1, 2026 -
Two biotechs raise a combined $556M in latest spurt of IPOs
April 30, 2026 -
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
April 29, 2026
